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BACKGROUND: In this study, we use a bioinformatics-
based strategy to nominate a tumor suppressor gene
cadherin-11 (CDH11) and investigate its role in growth
and invasion in head and neck squamous cell carcinoma
(HNSCC).
METHODS: Using the OncomineTM database to compare
HNSCC and normal specimens, CDH11 was nominated
as having a role in HNSCC. CDH11 expression in HNSCC
was evaluated by immunohistochemistry on a tissue
microarray (TMA) and immunoblotting and immunoflu-
orescence of cell lines. The functional impact of CDH11
on proliferation and invasion was evaluated after siRNA-
mediated knockdown.
RESULTS: In silico analysis suggested that CDH11 is
overexpressed in HNSCC compared to normal speci-
mens. HNSCC TMA exhibited a small but significant
increase in intensity and proportion of CDH11. By
immunoblot analysis, CDH11 was higher in 4/7 HNSCC
cell lines compared to normal keratinocytes; CDH11 was
highly upregulated in UM-SCC-47 and UM-SCC-74A and
detectable in UM-SCC-14A and UM-SCC-29 cell lines.
Downregulation of CDH11 in both UM-SCC-29 and
UM-SCC-47 using two different siRNAs enhanced prolif-
eration and invasion.
CONCLUSION: CDH11 inhibits cell proliferation and
invasion of HNSCC. This suggests that CDH11 functions
as a tumor suppressor gene in head and neck cancer. Our
findings emphasize the importance of verifying in silico
findings with functional studies.
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Introduction
In silico analysis of existing datasets has become an
important approach in identifying tumor-specific networks
and nominating molecular targets in head and neck squa-
mous cell carcinoma (HNSCC) (1). Translational researchers
use in silico analyses linked to clinical data to complement
laboratory research. Meta-analyses of existing microarray
data demonstrate correlations of markers across datasets
within a cancer type and across clinical stages. As the
importance of in silico analyses increases in translational
research studies, multiple platforms have been assembled for
bioinformatics analysis. The present study used OncomineTM,
which is a platform for meta-analysis of microarray datasets
each of which includes multiple normal and tumor samples
(2). Using this approach, we identified that Cadherin11
(CDH11), also known as osteoblasts-cadherin, is differen-
tially regulated in HNSCC and normal tissue.
CDH11, one of the type II classical cadherins, was first
identified in osteoblasts where it is an integral membrane
protein involved in cell–cell adhesion, potentially playing a
role in development and maintenance of bone (3). CDH11
promotes invasion and metastasis in prostate and breast
cancers, consistent with an oncogenic role (4, 5). In breast
cancer, CDH11 promotes metastases to the bone, due to the
high binding affinity of cancer cells for the strongly CDH11-
expressing osteoblasts. (4). In contrast, in esophageal,
colorectal and gastric cancers, CDH11 is silenced by
methylation and has a tumor suppressor role (6, 7). In
esophageal and nasopharyngeal cancer cells, CDH11 inhibits
invasion and migration (7). Due to the variability in CDH11
function, it is important to consider the cellular context. In the
present study, using an in silico approach, we nominated
CDH11 as having a role in HNSCC and investigated the
expression and function of CDH11 in HNSCC.
Materials and methods
In silico studies
The OncomineTM database (Compendia Bioscience, Ann
Arbor, MI, USA) was used for in silico studies. Eighteen
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head and neck cancer datasets were identified using the
search parameters ‘Cancer Type: Head and Neck Cancer’
and ‘Analysis Type: Cancer vs. Normal Analysis’. Datasets
from studies of adenoid cystic carcinoma, thyroid carcino-
mas and nasopharyngeal carcinomas were excluded. The
following studies were retained: Cromer Head- Neck (8),
Estilo Head-Neck (9), Ginos Head-Neck (10), Kuriakose
Head-Neck (11), Peng Head-Neck and Peng Head-Neck 2
(12), Pyeon Multi-cancer (Tongue, Oropharyngeal, Floor of
Mouth and Oral Cavity) (13), Schlingemann Head-Neck
(14), Talbot Lung (included tongue) (15), Toruner Head-
Neck (16), The Cancer Genome Atlas (TCGA) Head-Neck,
Ye Head-Neck (17). A summary of CDH11 overexpression
in multiple cancer types was generated. In addition,
correlation between CDH11 and epithelial to mesenchymal
transition (EMT) markers, E-Cadherin and Twist-1, was
evaluated from datasets in OncomineTM.
GraphPad Prism was used for statistical analyses.
HNSCC datasets with mRNA expression data (n = 15)
were identified in OncomineTM. Meta-analyses were per-
formed as described (18). Expression of CDH11 was
compared between normal and HNSCC samples by Stu-
dent’s t-test in each HNSCC dataset, and a P-value of <0.05
was determined to be statistically significant. Each statisti-
cally significant study was given an arbitrary value of ‘1’
and non-significant studies were assigned a value of ‘0’. A
one-sample t-test was performed for each set of values, and
a one-sided P-value of <0.05 was considered statistically
significant.
Immunohistochemistry
Immunostaining on formalin-fixed, paraffin-embedded tis-
sue and scoring of staining intensity was performed as
described (18) on a HNSCC tissue microarray (TMA) (US
Biomax. Rockville, MD, USA). The CDH11 affinity
purified rabbit polyclonal antibody (2.7 lg/ml) used for
immunohistochemical studies was from R&D Systems.
Rabbit IgG (Dako, Carpinteria, CA, USA) was used as a
negative control at the same concentration as the primary
antibody. For analysis of TMA data, interpretation and
scoring were performed by a board-certified pathologist as
described (18). The clinico-pathological parameters of the
HNSCC cases and CDH11 intensity and proportion scores
are included in Table S1.
Cell culture
UM-SCC cell lines were provided by Thomas Carey
(University of Michigan). Cells were genotyped to confirm
identity and cultured as described (18). All UM-SCC cell
lines were maintained in Dulbecco’s modified Eagle’s
medium (Gibco, Life Technologies, Grand Island, NY,
USA) supplemented with 10% FBS and 1% penicillin/
streptomycin. Immortalized keratinocytes, HOK16B,
obtained from Dr. NH Park (UCLA), were cultured as
described.
Transfection
To downregulate CDH11, HNSCC cells were transfected
with siRNA (Dharmacon, Lafayette, CO). The sequences for
each siRNA were: Non-Target 50-GUGAUUUCAUAGC-
GAGUUU-30, siCDH11-7 50-GGAAAUAGCGCCAAGUU
AG-30 andsiCDH11-850-CCUUAUGACUCCAUUCAAA-30.
UM-SCC-47 and UM-SCC-29 were seeded in a 6-well
plate and transfected with siRNA using RNAiMAX (Invit-
rogen, Carlsbad, CA, USA), according to the manufacturer’s
instructions.
Immunoblot
Lysates for detecting CDH11 were prepared using Red
Loading Buffer Pack (Cell Signaling, Danvers, MA, USA).
Lysates for detecting the other proteins were prepared using
1% NP40 lysis buffer (18). Antibodies used were CDH11
(A16652; Cell Signaling Technologies, Danvers, MA,
USA), Twist-1 (25465-1-AP; Proteintech, Chicago, IL,
USA), E-Cadherin (610182; BD Biosciences, Franklin
Lakes, NJ, USA), GAPDH (AB2302; Millipore, Billerica,
MA, USA), and Actin (612656; BD Biosciences).
Immunofluorescence staining
Cells were stained with E-cadherin (610182; BD Bio-
sciences) in 0.3% triton X-100 overnight at 4°C. Cells were
washed and incubated with secondary antibody and imaged
on a Nikon Eclipse Ti microscope.
In vitro proliferation and invasion assay
At 24–48 h post-transfection, cells were seeded at equal
densities (1 9 104 for UM-SCC-29, 2 9 104 for UM-SCC-
47). Viable, non-viable, and total cells were quantified at 1,
3, and 5 days using the Countess assay system (Invitrogen)
with trypan blue.
Cell invasion was assessed 24–72 h after transfection
using the modified Boyden chamber assay with Transwell
inserts coated with Matrigel (BD Biosciences), as described
(18). Inserts, not coated with matrigel, were used as a
control for migration.
Statistical analysis
P-values were calculated using the student’s t-test, a P-value
of less than 0.05 was accepted as significant. Correlation
coefficients (Spearman correlation) denoted by r, together
with a P-value, were computed to measure correlation
between different genes.
Results
HNSCC datasets provide extensive data for in silico studies
The OncomineTM database contained 986 datasets and
89 461 samples (accessed 04/24/2015). Of the available
datasets, 36 were identified as ‘Head and Neck Cancer’
datasets. Figure 1 gives an overview of the content of these
datasets. DNA or mRNA expression data are available for
the datasets (Fig. 1A). While most datasets contain less than
75 samples, about 20% contain more than 151 samples
(Fig. 1B). The data provided come from a range of sources,
including cell panels, tissue panels and TCGA, which was
compiled by the National Cancer Institute and National
Human Genome Research Institute (Fig. 1C). The speci-
mens used to generate the datasets include surgical speci-
mens and samples collected by laser-capture
microdissection, manual microdissection, and macrodissec-
tion (Fig. 1D). Several available search platforms for head
and neck cancer dataset analysis are listed in Table 1.
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Expression levels of biomarkers analyzed in the datasets can
be linked to clinically relevant parameters including sample
site, clinical outcomes, molecular subtypes, pathological
subtypes, drug sensitivities, and patient demographics.
CDH11 is overexpressed in cancer tissue compared to
normal tissue of patients in HNSCC
A summary of representative histograms detailing expres-
sion levels in individual studies used to compile the meta-
analyses of CDH11 is shown in Fig. 2A. Table 2 illustrates
systematic overexpression of CDH11 in HNSCC, including
a meta-analysis of the expression level in cancer vs. normal
across multiple datasets.
CDH11 is expressed in HNSCC tissue
In silico data suggested that CDH11 is overexpressed in
HNSCC. In order to validate the in silico findings, the
expression of CDH11 was investigated in tissues. In initial
studies, the antibody was optimized for immunohistochem-
istry on paraffin-embedded colon cancer tissue and associ-
ated tumor stroma, which are known to express CDH11
(19). After finding that CDH11 appropriately stained these
positive control tissues, a TMA containing human HNSCC
tissues and normal oral tissues was immunostained. CDH11
had low expression in normal tissue, and exhibited low,
medium or high staining in HNSCC (Fig. 2B). HNSCC
samples on the TMA exhibited a small but significant
increase in intensity of staining, and proportion of positive
HNSCC cells when compared to normal tissues (Fig. 2C).
These data confirm that CDH11 is expressed in HNSCC
tissues at higher levels than normal tissue.
Multiple HNSCC cell lines as well as a non-malignant
immortalized keratinocyte (HOK16B) cell line were
immunoblotted with the CDH11 antibody (Fig. 3A). These
data showed that CDH11 was upregulated in 4/7 HNSCC
cell lines compared to HOK16B. Invasion is a significant
Figure 1 Details of Head-Neck Cancer datasets. (A) A larger number of datasets provide mRNA expression (87%) levels than DNA copy-number analyses
(13%). (B) While most of the sample sets have <75 samples (59%), 20% contain more than 151 samples. (C) Data are supplied by a range of sources
including cell and tissue and data from sources including The Cancer Genome Atlas (TCGA), which is compiled by the National Cancer Institute and
National Human Genome Research Institute. (D) Samples represent a variety of sources, including cell lines, surgical specimens, and both macro and micro
dissections.
Table 1 Sample databases available for in silico studies in tumor/normal specimens
Database Access information Description
Cancer Gene Expression Database http://lifesciencedb.jp/cged/
Freely searchable.
A database of gene expression from studies performed in
Japanese institutions.
GENT – Gene Expression Across
Normal and Tumor tissue
http://medical-genome.kribb.re.kr/GENT/
Freely searchable.
A database of comparative gene expression across normal
and cancer tissues.
KEGG Database (Kyoto Encyclopedia
of Genes and Genomes)
http://www.genome.jp/kegg/kegg1.html
Freely searchable.
An integrated database of genomic and functional data,
links genes to higher level functions.
Oncomine https://www.oncomine.org/
Registration available to users from
educational, government and
non-profit institutions.
A compilation of cancer microarray data, search focus
can be narrowed very finely.
RefSeq – The Reference
Sequence Collection
http://www.ncbi.nlm.nih.gov/RefSeq/
Freely searchable, some content that
it links to requires additional access privileges.
The American NIH database of DNA, RNA and protein
sequences, provides detailed information on many of
these genes and proteins.
The Tumor Gene Family of Databases http://www.tumor-gene.org/Oral/oral.html
Freely searchable.
A set of databases of tumor suppressors, potential
oncogenes and cancer-inducing mutations.
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phenotype in HNSCC and is correlated with EMT and loss
of cell–cell adhesion. Since CDH11 differentially modulates
invasion, migration and metastasis in multiple cancers (4–7,
20), we investigated the correlation between expression of
EMT markers and CDH11. Epithelial marker E-cadherin
and mesenchymal marker Twist-1, and actin as a loading
control, were immunoblotted (Fig. 3B) in HNSCC lysates.
The data show that the E-Cadherin is upregulated in UM-
SCC-(11A, 14A, 17B, 29, 47) cell lines and Twist-1 was
downregulated in UM-SCC-(1, 11A, 14A, 17B, 29) cell
lines compared to HOK16B; 4/5 of these cell lines [UM-
SCC-(11A, 14A, 17B, 29)] showed an inverse relationship
between Twist-1 and E-cadherin. To investigate the func-
tional role of CDH11, we analyzed HNSCC datasets in
OncomineTM for potential correlation between CDH11 and
EMT markers, E-cadherin and Twist-1. We found a
dramatic positive correlation between CDH11 and E-
cadherin (Fig. 3C) and a significant negative correlation
between CDH11 and Twist-1 (Fig. 3D). The data suggested
that the high level of CDH11 may promote E-cadherin and
repress Twist-1 expression.
To confirm the bioinformatics data, UM-SCC-29 and
UM-SCC-47, which express low and high CDH11
(Fig. 3A), were selected for functional studies. Two
individual siRNAs were screened and downregulation was
verified by immunoblot (Fig. 3E,F). After CDH11 was
downregulated, epithelial and mesenchymal markers were
examined to determine whether CDH11 negatively regulates
EMT (Fig. 3G,H). In UM-SCC-29, which has low endoge-
nous CDH11, Twist-1 is inversely correlated with CDH11
expression, but the direct correlation with E-cadherin and
CDH11 is less prominent (Fig. 3G). In UM-SCC-47, which
has high endogenous CDH11, E-cadherin is directly corre-
lated with CDH11 and inversely correlated with Twist-1
expression (Fig. 3H). Importantly, a spindle-like EMT
morphologic appearance was observed after knockdown of
CDH11 in HNSCC cells (Fig. 4A). Furthermore, the
positive correlation between CDH11 and E-cadherin was
confirmed by immunofluorescence (Fig. 4B). Thus, CDH11
expression is correlated with a reverse EMT phenotype,
including upregulated epithelial marker E-cadherin and
downregulated mesenchymal marker Twist-1.
CDH11 inhibits proliferation and invasion in vitro
In order to investigate the functional role of CDH11,
proliferation and invasion assays were performed in UM-
SCC-29 and UM-SCC-47 cell lines using two siRNAs, si7
and si8. Our data show that downregulation of CDH11 in
Figure 2 CDH11 is expressed in cancer. (A) Meta-analysis showing CDH11 upregulation in cancer compared to normal tissue. Individual study sets and
accession numbers are identified in Table 2. (B) A TMA with HNSCC and normal tissues was incubated with CDH11 antibody followed by DAB detection.
(bar = 100 lm) (C) The intensity and proportion were scored (*P < 0.05).
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both cell lines by two different siRNAs significantly
increased proliferation at 72 and 120 h (Fig. 4C). Invasion,
an oncogenic phenotype that facilitates tumor spread, was
also significantly enhanced by knockdown of CDH11 at
72 h (Fig. 4D). These findings are consistent with the
reverse EMT phenotype observed in Fig. 3G,H. Together,
the functional studies support a tumor suppressive role for
CDH11 in HNSCC.
Discussion
Translational researchers are faced with the challenge of
addressing the gap between experimental studies and
implementation in clinical care. In silico investigations
using multiple datasets provide researchers with a practical
approach to enhancing benchtop investigations with clini-
cally oriented data or to discovery of potential biomarkers.
In the present study, we performed a meta-analysis of
multiple datasets using the OncomineTM platform. We
observed that CDH11 is overexpressed in HNSCC relative
to normal tissue across several datasets. Therefore, we
investigated the expression and function of CDH11, and
established that contrary to in silico findings, CDH11 has
anti-proliferative and anti-invasive effects in HNSCC. In the
context of a growing number of available genomic,
transcriptomic, metabolomic and proteomic datasets, the
present study highlights the importance of functionally
validating in silico findings.
Cadherins are transmembrane glycoproteins that regulate
homophilic intercellular adhesion by calcium-dependent
Figure 3 CDH11 expression correlates with a reverse epithelial to mesenchymal transition (EMT) phenotype. (A) Whole cell lysates of Immortalized
keratinocytes (HOK16B) as well as UM-SCC-1, -11A, -14A, -17B, -29, -47, -74A were immunoblotted with anti-CDH11; GAPDH was used as a loading
control. (B) Whole cell lysates of Immortalized keratinocytes (HOK16B) as well as UM-SCC-1, -11A, -14A, -17B, -29, -47, -74A were blotted with E-
Cadherin, Twist-1, and actin as a loading control. (C, D) Spearman analysis for correlation between CDH11 and EMT markers (E-Cadherin and Twist-1)
were conducted from multiple HNSCC database (C: Rickman Head-Neck, Ginos Head-Neck, Slebos Head-Neck, Pyeon Multi-cancer, Toruner Head-Neck,
Ye Head-Neck, O`Donnell Oral, Schlingemann Head-Neck, n = 270; D: Sengupta Head-Neck, Rickman Head-Neck, Pyeon Multi-cancer, Ye Head-Neck,
Bittner Multi-cancer, n = 191) from Oncomine (oncomine.org). Numbers represent r values with significance (P < 0.0001, P < 0.05, respectively). Two
individual siRNAs were investigated for efficiency in downregulating CDH11 in (E) UM-SCC-29 and (F) UM-SCC-47. After siRNA-mediated knockdown,
cell lysates from UM-SCC-29 (G) and UM-SCC-47 (H) were immunoblotted with anti-E-Cadherin and anti-Twist-1. Actin was run as a loading control.
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interactions (21). Cadherins contain a negatively charged
domain, which binds Ca2+ (3). The cytoplasmic domain is
divergent among cadherin family members (3). There are
over 80 members in the cadherin superfamily (3). CDH11 is
a member of the ‘classical’ cadherin subclass of the cadherin
superfamily (21). Type I Classical cadherins include E-
cadherin/cadherin 1, N-cadherin/cadherin 2, R-cadherin/
cadherin 4, P-cadherin or cadherin 3. Type II Classical
cadherins include CDH11 (21). Other cadherins include
protocadherins, desmosomal cadherins, seven-pass trans-
membrane cadherins, and Ret tyrosine kinase (21). Classical
cadherins regulate cell–cell interactions, tissue homeostasis,
and tissue morphogenesis; given these important roles,
disruption of these proteins leads to disease (22). Cadherin
homodimers on one cell bind homodimers on another cell to
form transdimers that facilitate cell–cell adhesion (21).
The gene for CDH11 is located on chromosome 16 (3).
CDH11 is usually expressed in mesenchymal cells and
facilitates adhesion between these cells (23). CDH11
expression correlates with osteoblast-differentiation and
promotes chondro-osteogenesis and inhibits adipogenesis
(3, 21). Consistent with an oncogenic role, CDH11,
promotes invasion of prostate cancer cells and metastasis
to bone (5, 20). CDH11 expression is upregulated in
colorectal tumors (24). In oral squamous cell carcinoma, a
previous immunohistochemical study showed that CDH11
is overexpressed but did not perform functional studies (25).
In the present study, in silico studies and TMAs of human
HNSCC suggested that CDH11 is overexpressed in
HNSCC. Some HNSCC sections showed high CDH11
whereas in other sections, the expression was not as
impressive. Together, these findings yielded an overall
significant difference in expression of CDH11 between
HNSCC and normal tissue. This is supported by immuno-
blot analysis showing overexpression of CDH11 in four out
of seven HNSCC cell lines compared to normal ker-
atinocytes. This suggests that overexpression of CDH11 is
cancer-specific and is overexpressed in some and not in
other HNSCCs. This is consistent with the heterogeneity of
HNSCC and emphasizes the importance of personalized
medicine in HNSCC. Importantly, in functional studies, we
found that downregulation of CDH11 promotes proliferation
and enhances invasion, consistent with a tumor suppressor
role for CDH11. These findings are consistent with the
recently reported loss of CDH11 expression in melanoma as
a widespread event (26). Similarly, CDH11 undergoes
genomic deletion in retinoblastomas (6) and its loss
correlates with increased invasion. Studies in retinoblastoma
(6) and malignant pheochromocytoma (27) showed that
CDH11 potently suppresses tumor metastasis. Moreover,
CDH11 expression reduced metastatic potential in lung
cancer and represented a beneficial prognostic factor in
osteosarcoma (28). Since the oncogenic vs. tumor suppres-
sive function of CDH11 varies by cancer, it is important to
consider the specific cancer type. Furthermore, different
tumors within a subtype may differ in CDH11 expression. In
the emerging area of personalized medicine, variation in
CDH11 expression may be relevant to tumor behavior.
Figure 4 Downregulation of CDH11 in UM-SCC-29 and UM-SCC-47 cells promoted proliferation and invasion. (A) Morphology changes of UM-SCC-29
and UM-SCC-47 cells transfected with siNT or siCDH11 by phase-contrast microscopy. Original magnification, 9100 (bar = 200 lm). (B) UM-SCC29 and
UM-SCC-47 cells were stained with Cadherin (green) antibodies and DAPI (blue) after transfection with siCDH11. (bar = 100 lm). (C) UM-SCC-29 and
UM-SCC-47 cells were transfected with siCDH11 (si7, si8) or NT siRNA. UM-SCC-29 and UM-SCC-47 cells were seeded in triplicate at 48 h after
transfection in a 24-well plate and cells were counted at 1, 3, and 5 days after seeding. Total viable cells are shown. *P < 0.05 at 72 h and at 120 h. (D) Cell
invasion was assessed at 72 h in UM-SCC-29 and UM-SCC-47 cells transfected with siCDH11 (si7, si8) or NT siRNA. *P < 0.05 at 72 h.
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Data mining of publically available datasets was used to
nominate novel oncogenes having a role in epithelial-
mesenchymal transition in HNSCC. This study was the first
to analyze the expression of CDH11 using an in silico
experiment and verify its tumor suppressor role in HNSCC.
In this role, CDH11 inhibits invasion and proliferation in
HNSCC. Interestingly, CDH11 expression is inversely
correlated with EMT, which has been shown to be an
important event in invasion (29). This may occur via the
Wnt/b-catenin pathway. A previous study showed that
CDH11 is a functional tumor suppressor and an important
regulator of Wnt/b-catenin signaling involved in EMT, with
frequent epigenetic inactivation in common carcinomas
(7).We showed previously that b-catenin promotes invasion
in HNSCC (30). Future studies are needed to investigate this
possibility.
In summary, we analyzed CDH11 expression in HNSCC
by meta-analysis of fifteen datasets in the OncomineTM
database. These findings were verified by expression
studies in multiple cell lines and HNSCC tissue. Impor-
tantly, we observed that CDH11 is a tumor suppressor in
functional studies. Further investigations are needed to
determine the mechanism of CDH11-mediated inhibition
of invasion.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1 The clinico-pathological parameters of the
HNSCC cases and CDH11 intensity and proportion scores.
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